Cardiovascular and biochemical responses to nebulised salbutamol in normal subjects.
作者信息
Smith S R, Ryder C, Kendall M J, Holder R
出版信息
Br J Clin Pharmacol. 1984 Oct;18(4):641-4. doi: 10.1111/j.1365-2125.1984.tb02520.x.
Abstract
When conventional therapeutic doses of nebulised salbutamol were given to normal volunteers, there was a significant rise in pulse rate, systolic blood pressure and plasma glucose and a significant fall in diastolic blood pressure and serum potassium in comparison with placebo. Such changes may be potentially hazardous in certain situations. Patients with airways obstruction due to chronic bronchitis who have coexistent ischaemic heart disease or diuretic induced hypokalaemia may be at particular risk from the unwanted cardiovascular and biochemical responses to nebulised salbutamol.
摘要
相似文献
1
Cardiovascular and biochemical responses to nebulised salbutamol in normal subjects.
Br J Clin Pharmacol. 1984 Oct;18(4):641-4. doi: 10.1111/j.1365-2125.1984.tb02520.x.
2
Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.
Br J Clin Pharmacol. 1988 May;25(5):571-8. doi: 10.1111/j.1365-2125.1988.tb03347.x.
3
Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.
Thorax. 1997 Oct;52(10):849-52. doi: 10.1136/thx.52.10.849.
4
Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol.
Br J Clin Pharmacol. 1980 May;9(5):483-91. doi: 10.1111/j.1365-2125.1980.tb05844.x.
5
Beta-adrenoceptor responses to inhaled salbutamol in normal subjects.
Eur J Clin Pharmacol. 1989;36(3):239-45. doi: 10.1007/BF00558154.
6
Air-driven nebulised high-dose salbutamol in severe chronic obstructive airways disease: is it safe?
Respiration. 1991;58(5-6):249-54. doi: 10.1159/000195940.
7
Modulation of the effects of salbutamol by propranolol and atenolol.
Eur J Clin Pharmacol. 1989;36(5):449-53. doi: 10.1007/BF00558068.
8
The extrapulmonary effects of inhaled hexoprenaline and salbutamol in healthy individuals.
Eur J Clin Pharmacol. 1993;45(1):37-9. doi: 10.1007/BF00315347.
9
Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study.
Br J Clin Pharmacol. 2009 Apr;67(4):394-402. doi: 10.1111/j.1365-2125.2009.03377.x.
10
Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol.
Curr Med Res Opin. 1975;3(1):30-5. doi: 10.1185/03007997509113642.
引用本文的文献
1
Salbutamol in the Management of Asthma: A Review.
Int J Mol Sci. 2022 Nov 17;23(22):14207. doi: 10.3390/ijms232214207.
2
Do medicines commonly used by older adults impact their nutrient status?
Explor Res Clin Soc Pharm. 2021 Sep 3;3:100067. doi: 10.1016/j.rcsop.2021.100067. eCollection 2021 Sep.
3
Nebulisers for the elderly.
Thorax. 1997 Apr;52 Suppl 2(Suppl 2):S53-5. doi: 10.1136/thx.52.2008.s53.
4
The effect of salbutamol on performance in endurance cyclists.
Eur J Appl Physiol Occup Physiol. 1996;73(3-4):364-8. doi: 10.1007/BF02425500.
5
Treatment of hyperkalaemia using intravenous and nebulised salbutamol.
Arch Dis Child. 1994 Feb;70(2):126-8. doi: 10.1136/adc.70.2.126.
6
The dose-related hyper-and-hypokalaemic effects of salbutamol and its arrhythmogenic potential.
Br J Pharmacol. 1994 Jan;111(1):73-6. doi: 10.1111/j.1476-5381.1994.tb14025.x.
7
Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.
Br J Clin Pharmacol. 1986 Apr;21(4):451-3. doi: 10.1111/j.1365-2125.1986.tb05221.x.
8
Adverse reactions to beta 2-agonist bronchodilators.
Med Toxicol. 1986 Jul-Aug;1(4):286-99. doi: 10.1007/BF03259844.
9
The effects of ketotifen on beta-adrenergic activity in asthmatics.
Eur J Clin Pharmacol. 1988;34(6):585-9. doi: 10.1007/BF00615221.
10
Modulation of the effects of salbutamol by propranolol and atenolol.
Eur J Clin Pharmacol. 1989;36(5):449-53. doi: 10.1007/BF00558068.
本文引用的文献
1
Diuretic-induced ventricular ectopic activity.
Am J Med. 1981 Apr;70(4):762-8. doi: 10.1016/0002-9343(81)90530-1.
2
Cardiovascular and metabolic effects of terbutaline.
J Clin Hosp Pharm. 1982 Mar;7(1):31-6. doi: 10.1111/j.1365-2710.1982.tb00905.x.
3
Comparison of inhaled and intravenous terbutaline in acute severe asthma.
Thorax. 1981 Aug;36(8):629-31. doi: 10.1136/thx.36.8.629.
4
Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels.
Thorax. 1981 Aug;36(8):625-8. doi: 10.1136/thx.36.8.625.
5
Nebulised salbutamol and angina.
Br Med J (Clin Res Ed). 1982 Sep 18;285(6344):796-7. doi: 10.1136/bmj.285.6344.796.
6
Systemic effects of inhalation of terbutaline with IPPB in normal subjects.
Scand J Respir Dis. 1974;55(1):19-24.
7
The metabolic effects of inhaled salbutamol.
Br J Clin Pharmacol. 1978 Feb;5(2):127-9. doi: 10.1111/j.1365-2125.1978.tb01612.x.
8
Metabolic effects of salbutamol: comparison of aerosol and intravenous administration.
Br Med J. 1977 Feb 12;1(6058):413-4. doi: 10.1136/bmj.1.6058.413.
Zotero 插件